Raise a Glass? Study Tallies Cancer Cases From Booze Heavy drinking habits accounted for about half of new alcohol-associated cases Jul 13, 2021
Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer? Use of chemo reduced radiation-induced cancers, and may prolong OS in low-PSA subgroup Jul 07, 2021
Infusion Centers or EDs for Sickle Cell Crises? Adults with SCD treated in infusion centers had improved outcomes in three key measures Jul 06, 2021
IVF Babies at No Increased Risk of Childhood Cancers No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
Hold Off on Approving Anal Cancer Drug, Advisors Tell FDA ODAC recommends deferring approval of new PD-1 inhibitor until confirmatory trial results are in Jun 24, 2021
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma Prolonging PFS a positive, as advances make OS improvement harder to achieve Jun 18, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
Fixed-Duration, All-Oral Regimen Slows CLL Progression Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma Better response rates and survival with axicabtagene ciloleucel versus external control group Jun 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
Another CAR-T Impresses in Follicular Lymphoma Complete responses in 66% of patients with relapsed or refractory disease Jun 08, 2021
Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
With Supplements, ADT in Prostate Cancer of Little Threat to Bone Density Study suggests calcium/vitamin D alone sufficient for long-duration therapy Jun 03, 2021
Family Alleges Profit Motives Played Role in 3-Year-Old's Death Parents charge care delays for child with hydrocephalus were tied to arrangements for star doctor May 25, 2021
Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma Commonly used regimens with autologous transplant improved survival May 06, 2021
Vadadustat Matches Standard for CKD-Related Anemia, With Caveat Jury still out on drug's heart safety, which differed depending on dialysis dependence Apr 28, 2021
Healthy Lifestyle May Mitigate Heart Risks for Young Cancer Survivors Literature reviews find particularly persistent cardiovascular complications in these patients Apr 28, 2021
Why Clotting Happens When Platelets Are Low A hematologist explains the counterintuitive concept of clots with low platelets Apr 23, 2021
Poloxamer 188 Flops for Sickle Cell Disease Pain Study found no difference in duration of vaso-occlusive episodes versus placebo Apr 20, 2021
Targeted Drug Yields Durable Responses in Rare Blood Neoplasm Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
From VIPIT to VITT: Thrombosis and COVID Vaccines More data support link between adenovirus vector vaccines, blood clotting, and low platelets Apr 09, 2021
Ethics Consult: Stop Treatment for Costly Patient? MD/JD Weighs In You voted, now see the results and an expert's discussion Apr 09, 2021
Vaccines and Rare Clotting Disorders: What's the Link? Causal relation appears possible, but evidence still indicates it's extremely rare Mar 25, 2021
Marrow Cell Stimulator to Treat Alzheimer's Disease? Unusual approach pans out in mid-stage trial Mar 24, 2021
Op-Ed: Blood Cancer Patients Need More COVID Vax Answers Patients are left wondering, "will I be protected?" Mar 24, 2021
C3 Inhibitor Prevails in Trial of Rare Hemoglobinuria Improvement in hemoglobin, transfusion independence with pegcetacoplan for PNH Mar 17, 2021
Holding tPA for All DOAC Users Not the Way to Go, Stroke Docs Say Clinical conundrum could be solved by a point-of-care DOAC test Mar 15, 2021
Study Confirms Risk-Adapted CRS Prophylaxis for Acute Leukemia Tocilizumab reduced severe cytokine release syndrome in children, young adults Mar 09, 2021
Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients Plus: Active chemo treatment may not be a COVID risk factor Feb 05, 2021
Preventive Approach to C-Section Bleeding Pans Out in Trial Treatment lowered risk of early blood loss and transfusion, but not more severe hemorrhage Jan 29, 2021
Officials Investigate Physician's Death After COVID Vaccination Onset of rare blood disorder should not be interpreted as causal, experts say Jan 27, 2021
JAK Inhibitor Misses Endpoint in Safety Study. Now What? Major blow to popular class of oral rheumatology drugs Jan 27, 2021
Ethics Consult: Refuse Treatment for Dictator? MD/JD Weighs In You voted, now see the results and an expert's discussion Jan 15, 2021
PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease Odronextamab, epcoritamab surpass 90% response threshold in early trials Dec 11, 2020
Chemo-Free Combo Boosts PFS in First-Line CLL PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting Dec 08, 2020
Novel Agent Active in Refractory CML Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy Dec 08, 2020
